Cdc7-IN-5

• CAT Number: I017551
• CAS Number: 1402057-86-6
• Molecular Formula: C₂₅H₂₃N₃O₅
• Molecular Weight: 445.47
• Purity: ≥95%
• Target: CDK
• IUPAC Name: ethyl 4-hydroxy-2-(7-methoxy-3,4-dihydro-1H-isoquinolin-2-yl)-5-[(Z)-pyrrolo[2,3-b]pyridin-3-ylidenemethyl]furan-3-carboxylate
• InChI: InChI=1S/C25H23N3O5/c1-3-32-25(30)21-22(29)20(12-16-13-27-23-19(16)5-4-9-26-23)33-24(21)28-10-8-15-6-7-18(31-2)11-17(15)14-28/h4-7,9,11-13,29H,3,8,10,14H2,1-2H3/b16-12+
• InChIKey: JSRLUFXDTSIAKH-FOWTUZBSSA-N
• SMILES: CCOC(=O)C1=C(OC(=C1O)/C=C/2\C=NC3=C2C=CC=N3)N4CCC5=C(C4)C=C(C=C5)OC

Cdc7-IN-5（Cat No.:I017551）is a selective inhibitor of the Cdc7 kinase, which plays a critical role in the initiation of DNA replication. By disrupting Cdc7 activity, this compound effectively impairs cell cycle progression, leading to the inhibition of tumor cell proliferation. Cdc7-IN-5 has shown potential in preclinical studies for its efficacy against various cancer types, particularly those with aberrant cell cycle regulation. Its specificity for Cdc7 reduces off-target effects, making it a promising candidate for targeted cancer therapies. Ongoing research aims to evaluate its safety and effectiveness in clinical settings.

Reference

[1]. Christian Andrew HASSIG, et al. Methods of treatment of cancer comprising cdc7 inhibitors. WO2019165473A1.